GlassScriptPhysician profile
Meredith Mclain Griffin
NPI 1598953705
$10,526.54
in general payments reported to CMS, 2019-2025
43 companies · $1,995 in 2025
The $1,995 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,470 · 2022: $2,010 · 2023: $2,193 · 2024: $1,857 · 2025: $1,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,045.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,158.26 | 2021-2025 | Freestyle Libre, Freestyle Libre 3, Eterna |
| Insulet Corporation | $835.27 | 2021-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $727.49 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $711.60 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Medtronic, INC. | $628.96 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Novo Nordisk INC | $598.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $526.60 | 2021-2023 | Afrezza |
| Beta Bionics, INC. | $466.85 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sanofi-Aventis U.S. LLC | $442.65 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $432.43 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $404.11 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $349.91 | 2022-2024 | Cequr Simplicity |
| Abbvie INC. | $312.43 | 2021-2025 | |
| Corcept Therapeutics | $289.36 | 2021-2025 | Korlym |
| Esperion Therapeutics, INC. | $277.42 | 2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $243.56 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $234.40 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amneal Pharmaceuticals LLC | $204.58 | 2023-2024 | Unithroid |
| Ascensia Diabetes Care US INC. | $176.27 | 2023-2024 | |
| Amgen INC. | $174.60 | 2021-2025 | Tepezza, Repatha |
| Kyowa Kirin, INC. | $122.46 | 2023-2025 | Crysvita |
| Ibsa Pharma INC. | $115.61 | 2021-2024 | Tirosint, Licart, Tirosint |
| Zealand Pharma US, INC. | $110.57 | 2021-2022 | |
| Dexcom, INC. | $109.06 | 2022-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $99.62 | 2022-2024 | Strensiq |
| Antares Pharma, INC. | $76.82 | 2022-2024 | Xyosted |
| Amarin Pharma, INC. | $70.94 | 2021-2022 | |
| Radius Health, INC. | $70.47 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $65.43 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $63.98 | 2024-2025 | Isturisa, Signifor Lar |
| Madrigal Pharmaceuticals | $56.94 | 2025 | Rezdiffra |
| Clarus Therapeutics INC. | $47.67 | 2021 | |
| Ascendis Pharma Endocrinology INC | $43.49 | 2023-2025 | Yorvipath |
| Horizon Therapeutics Plc | $38.02 | 2021-2023 | Tepezza |
| Astellas Pharma US INC | $37.87 | 2023-2024 | Veozah |
| Halozyme INC | $37.46 | 2023 | |
| Amryt Pharma Holdings LTD | $35.25 | 2022-2023 | Mycapssa |
| Nevro Corp. | $29.57 | 2022 | |
| Vistapharm, INC. | $25.99 | 2021 | |
| Chiesi USA, INC. | $20.99 | 2025 | Mycapssa |
| Lifescan, INC. | $20.78 | 2022 | |
| Medicure Pharma INC. | $20.39 | 2021 | |
| Acerus Pharmaceuticals Corporation | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.